hepatorenal.blogspot.com
Hepatorenal Syndrome: 7/27/08 - 8/3/08
http://hepatorenal.blogspot.com/2008_07_27_archive.html
Thursday, July 31, 2008. Complications of Transjugular Intrahepatic Portosystemic Shunt. Complications of Transjugular Intrahepatic Portosystemic Shunt. The development of strategies to prevent shunt stenosis is the focus of active research. Potential strategies include pharmacologic approaches to reduce shunt intimal hyperplasia, the primary cause of stenosis, and engineering and testing of stents covered by selectively permeable materials like polytetrafluoroethylene. Severe hepatic encephalopathy poor...
hepatorenal.blogspot.com
Hepatorenal Syndrome
http://hepatorenal.blogspot.com/2009/03/midodrine-orthostatic-hypotension.html
Friday, March 6, 2009. Midodrine hydrochloride is administered orally, usually in 3 equally divided doses daily. Since food does not appear to affect GI absorption of midodrine hydrochloride, the drug generally can be administered without regard to meals. Dosage in Renal and Hepatic Impairment. Adverse Effects List from First Databank. BURNING,ITCHING,PRICKLING OF SCALP, CHILLS, HYPERTENSION (severe), SUPINE HYPERTENSION (severe), URINARY FREQUENCY, URINARY RETENTION. Rare or Very Rare. ANIMAL STUDIES HA...
samirapas.blogspot.com
Antiphospholipid Antibody Syndrome: Jun 10, 2008
http://samirapas.blogspot.com/2008_06_10_archive.html
Tuesday, June 10, 2008. ANTIPHOSPHOLIPID ANTIBODIES (APLA)-DEFINITIONS AND HISTORY. One major difficulty in studying APLA is that no one really knows what the underlying pathogenic mechanism is that leads to the clinical syndrome. This review will side-step this issue (best reviewed in the McNeil paper) and concentrate on clinical matters. TESTS FOR ANTIPHOSPHOLIPID ANTIBODIES (APLA). APTT will correct to normal at time 0 and stay in the normal range on each of the time points. This test is very sensitiv...
hepatorenal.blogspot.com
Hepatorenal Syndrome: 3/1/09 - 3/8/09
http://hepatorenal.blogspot.com/2009_03_01_archive.html
Friday, March 6, 2009. Midodrine hydrochloride is administered orally, usually in 3 equally divided doses daily. Since food does not appear to affect GI absorption of midodrine hydrochloride, the drug generally can be administered without regard to meals. Dosage in Renal and Hepatic Impairment. Adverse Effects List from First Databank. BURNING,ITCHING,PRICKLING OF SCALP, CHILLS, HYPERTENSION (severe), SUPINE HYPERTENSION (severe), URINARY FREQUENCY, URINARY RETENTION. Rare or Very Rare. ANIMAL STUDIES HA...
hepatorenal.blogspot.com
Hepatorenal Syndrome: 6/22/08 - 6/29/08
http://hepatorenal.blogspot.com/2008_06_22_archive.html
Friday, June 27, 2008. Http:/ www.blogger.com/img/gl.align.full.gif. Transjugular intrahepatic portosystemic shunts. Only a few studies have reported on the effects of. Transjugular intrahepatic portosystemic shunts (TIPS) in. Patients with type 1 HRS. This procedure consists of. Insertion of an intrahepatic stent between the portal and. Hepatic veins by a transjugular approach. The main effect. Is to lower portal pressure. In type 1 HRS, TIPS improve. Circulatory function and reduce the activity of.
hepatorenal.blogspot.com
Hepatorenal Syndrome: 6/8/08 - 6/15/08
http://hepatorenal.blogspot.com/2008_06_08_archive.html
Saturday, June 14, 2008. Refers to renal failure of unknown etiology that occurs in a fully hydrated patient with severe, often progressive, liver disease. Urine biochemistry is characteristic and renal histopathology unremarkable. The urine sediment should be examined carefully. The presence of cellular casts suggests vasomotor nephropathy rather than hepatorenal syndrome. Obstructive uropathy should be excluded by renal ultrasonography or, if necessary, retrograde pyelography. Subscribe to: Posts (Atom).
hepatorenal.blogspot.com
Hepatorenal Syndrome: Complications of Transjugular Intrahepatic Portosystemic Shunt
http://hepatorenal.blogspot.com/2008/07/complications-of-transjugular.html
Thursday, July 31, 2008. Complications of Transjugular Intrahepatic Portosystemic Shunt. Complications of Transjugular Intrahepatic Portosystemic Shunt. The development of strategies to prevent shunt stenosis is the focus of active research. Potential strategies include pharmacologic approaches to reduce shunt intimal hyperplasia, the primary cause of stenosis, and engineering and testing of stents covered by selectively permeable materials like polytetrafluoroethylene. Subscribe to: Post Comments (Atom).
samirapas.blogspot.com
Antiphospholipid Antibody Syndrome: Jun 22, 2008
http://samirapas.blogspot.com/2008_06_22_archive.html
Sunday, June 22, 2008. The syndromes of insulin resistance actually comprise a broad clinical spectrum. These include patients with obesity, glucose intolerance, diabetes, syndrome X, and patients with an extreme insulin-resistant state. Many of these disorders are associated with various endocrine, metabolic, and genetic conditions. The syndromes also may be associated with immunological diseases and may exhibit distinct phenotypic characteristics. Links to this post. Subscribe to: Posts (Atom).
samirapas.blogspot.com
Antiphospholipid Antibody Syndrome: Feb 20, 2009
http://samirapas.blogspot.com/2009_02_20_archive.html
Friday, February 20, 2009. Disorders Disorders Associated with Triglyceride Levels. Disorders Associated with Triglyceride Levels. Familial Defective Apolipoprotein B-100. Links to this post. Subscribe to: Posts (Atom). Disorders Disorders Associated with Triglyceride L. FEEDJIT Live Traffic Map. FEEDJIT Live Traffic Feed.
